Incurable diseases may not be so tomorrow. From cancers to degenerative diseases, from rare diseases to certain chronic syndromes, innovative drugs could radically change the situation.
Biopharmaceuticals are a major opportunity for the pharmaceutical industry. Their active ingredient is made from living organisms. They include vaccines, gene therapies, recombinant proteins, monoclonal antibodies. They are the agents of choice in targeted therapies, especially in oncology, distinguishing themselves from the traditional cytotoxic chemotherapy.
On the current $1 trillion pharmaceutical market, biopharmaceuticals account for about 25%, a fraction that will grow to 50% within a decade. Their annual turnover is estimated at $800 billion by 2030.